Bluebird’s Zynteglo Shows Long-Term Efficacy And Safety Amid US Commercialization Push

Data presented at ASH show patients maintaining transfusion independence for years after infusion, months after bluebird won FDA approval for the beta-thalassemia gene therapy.

Bluebird presented long-term data for Zynteglo at ASH 2022 • Source: Shutterstock

Zynteglo (betibeglogene autotemcel), bluebird bio’s gene therapy for transfusion-dependent beta-thalassemia (TDT), inched closer to proving it is potentially curative with data at the American Society of Hematology meeting showing efficacy was maintained in patients with seven years’ worth of follow-up. That could help bolster the case for the treatment as the company works to commercialize it.

The ASH annual meeting, held 10-13 December in New Orleans, included a poster with long-term outcomes data for Zynteglo from...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies